United Therapeutics reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%

Reuters

03/12

United <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%

United Therapeutics reported full Phase 3 TETON-2 trial results for nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) that were published in The New England Journal of Medicine. The study met its primary endpoint, with median forced vital capacity $(FVC)$ change at week 52 of -49.9 mL with Tyvaso versus -136.4 mL with placebo. Tyvaso reduced the risk of a clinical worsening event by 29% versus placebo (hazard ratio 0.71). The randomized, double-blind trial enrolled 597 patients (298 Tyvaso; 295 placebo), and 75% were on background antifibrotic therapy. United Therapeutics said it plans to submit a supplemental New Drug Application to the FDA in the second half of 2026 following results from the ongoing TETON-1 study, which it said are expected soon.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111814BIZWIRE_USPR_____20260311_BW495225) on March 11, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2618971817"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618971817\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618971817?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 06:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618971817","market":"us","top_or_hot":-1,"title":"United Therapeutics reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        United Therapeutics reported full Phase 3 TETON-2 trial results for nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) that were published in The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine. The study met its primary endpoint, with median forced vital capacity <a href=\"https://laohu8.com/S/FVC\">$(FVC)$</a> change at week 52 of -49.9 mL with Tyvaso versus -136.4 mL with placebo. Tyvaso reduced the risk of a clinical worsening event by 29% versus placebo (hazard ratio 0.71). The randomized, double-blind trial enrolled 597 patients (298 Tyvaso; 295 placebo), and 75% were on background antifibrotic therapy. United Therapeutics said it plans to submit a supplemental New Drug Application to the FDA in the second half of 2026 following results from the ongoing TETON-1 study, which it said are expected soon.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111814BIZWIRE_USPR_____20260311_BW495225) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 06:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        United Therapeutics reported full Phase 3 TETON-2 trial results for nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) that were published in The <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine. The study met its primary endpoint, with median forced vital capacity <a href=\"https://laohu8.com/S/FVC\">$(FVC)$</a> change at week 52 of -49.9 mL with Tyvaso versus -136.4 mL with placebo. Tyvaso reduced the risk of a clinical worsening event by 29% versus placebo (hazard ratio 0.71). The randomized, double-blind trial enrolled 597 patients (298 Tyvaso; 295 placebo), and 75% were on background antifibrotic therapy. United Therapeutics said it plans to submit a supplemental New Drug Application to the FDA in the second half of 2026 following results from the ongoing TETON-1 study, which it said are expected soon.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111814BIZWIRE_USPR_____20260311_BW495225) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLb2L9vp:1","article_id":"2618971817","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618971817","pubTimestamp":1773267276,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"United Therapeutics reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%. United Therapeutics reported full Phase 3 TETON-2 trial results for nebulized Tyvaso  in idiopathic pulmonary fibrosis  that were published in The New England Journal of Medicine. The study met its primary endpoint, with median forced vital capacity  change at week 52 of -49.9 mL with Tyvaso versus -136.4 mL with placebo. Tyvaso reduced the risk of a clinical worsening event by 29% versus placebo . The randomized, double-blind trial enrolled 597 patients , and 75% were on background antifibrotic therapy. United Therapeutics said it plans to submit a supplemental New Drug Application to the FDA in the second half of 2026 following results from the ongoing TETON-1 study, which it said are expected soon.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"United Therapeutics报告TETON-2 3期试验显示Tyvaso可保留IPF患者的肺功能并将临床恶化风险降低29%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":0.9},"content_text":"United Therapeutics reports TETON-2 Phase 3 trial shows Tyvaso preserves lung function in IPF and cuts clinical worsening risk 29%\n    \n\n        United Therapeutics reported full Phase 3 TETON-2 trial results for nebulized Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) that were published in The New England Journal of Medicine. The study met its primary endpoint, with median forced vital capacity $(FVC)$ change at week 52 of -49.9 mL with Tyvaso versus -136.4 mL with placebo. Tyvaso reduced the risk of a clinical worsening event by 29% versus placebo (hazard ratio 0.71). The randomized, double-blind trial enrolled 597 patients (298 Tyvaso; 295 placebo), and 75% were on background antifibrotic therapy. United Therapeutics said it plans to submit a supplemental New Drug Application to the FDA in the second half of 2026 following results from the ongoing TETON-1 study, which it said are expected soon.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202603111814BIZWIRE_USPR_____20260311_BW495225) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}